C3 Working with Stand Up to Cancer Initiative

C3 will represent people touched by colorectal cancer with the Stand Up to Cancer (SU2C) initiative by serving on the SU2C Advocacy Advisory Council. “Our role as advocates is to help shape the direction of the exciting research that will be funded by SU2C,” said Nancy Roach, C3 Board of Directors.

SU2C is a national effort to raise substantial monies for ground-breaking translational cancer research that will accelerate advances in patient care as well as in cancer prevention.   A program of the Entertainment Industry Foundation, SU2C was established by a group of media, entertainment, and philanthropic leaders whose lives have all been affected by cancer in significant ways. They have partnered with American Association for Cancer Research (AACR) to provide expert scientific oversight of this important initiative.

The centerpiece of this initiative will be a nationally televised fundraising event to air on September 5, 2008.  The networks have joined together in an unprecedented collaboration to donate one hour of simultaneous, commercial-free prime time for this program.

Continue reading…

Posted by Carlea Bauman on May 27th, 2008
Posted in: C3 News | 3 Comments »
Tags: aacr, Advocacy, cancer research, entertainment industry foundation, fundraising event

Welcome to the new FightColorectalCancer.org!

Welcome to our newly redesigned website!

More than just a fresh coat of paint, we’ve listened to your comments over the past 3 years and we’ve made the C3 site better than ever.

We hope you find the new site easier to navigate and search. You’ve come to rely on us for the most up-to-date research and treatment news, as well as the latest on what you can do to help us win the fight against colorectal cancer. That is not changing. In fact, we’ve made it easier than ever for you to subscribe to the latest site updates by RSS or email.

Be sure to explore the expanded Patient Information section. If there’s a particular term you’re looking for, you can now search our site from every page.

We’d like to thank Erik J. Barzeski and ACS (not that ACS) for their technical and design expertise which helped make this new site possible.

Please be patient with us as the site changes to the new look & feel. Let us know what you think (or any problems that you find) by leaving us a comment. We’d love to hear from you!

Posted by Judi Sohn on May 13th, 2008
Posted in: C3 News | No Comments »

May is National Cancer Research Month

May has been set aside as National Cancer Research Month by Congressional resolutions in both the United States House of Representatives and United States Senate.

During May researchers, advocates, and patients are focusing on how far cancer research has brought us in preventing and treating cancer . . . and how far we have to go to end death and suffering from cancer. Continue reading…

Posted by Kate Murphy on May 13th, 2008
Posted in: C3 News | No Comments »

Duke-FDA Coalition Names C3 Board Chair to Clinical Trial Initiative

The Clinical Trials Transformation Initiative (CTTI), a growing, broad-based coalition of organizations dedicated to modernizing the way clinical trials are conducted in the United States, has named a 12-member Executive Board that will oversee its activities.

Founded by the U.S. Food and Drug Administration (FDA) and Duke University as a public-private partnership, CTTI seeks to improve the quality and efficiency of clinical trials. CTTI was formed in the wake of growing frustration among patients, consumers, the academic community and industry over the difficulty of conducting high-quality clinical trials in a timely manner that could produce information physicians need to define optimal treatments for their patients.

This board comprises leading figures in government, academia, industry (pharmaceutical, biotechnology, device and contract research) and patient advocacy.

C3 Board Chair Nancy Roach has been named a member of the CTTI Executive Board as the only representative of the patient advocacy community.

Posted by Judi Sohn on May 12th, 2008
Posted in: C3 News, Research & Treatment News | 1 Comment »